Company intelligence / Profile preview

Spruce Ventures

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Spruce Biosciences shifted focus from CAH to Sanfilippo Syndrome Type B treatment in 2024. The company acquired tralesinidase alfa enzyme replacement therapy (TA-ERT) from BioMarin Pharmaceutical and received FDA breakthrough therapy designation in October 2025, driving significant stock appreciation.

Therapeutic areas: EndocrinologyRare Diseases
Modalities: Small moleculeEnzyme replacement therapy
Industry: Biotech

Partnerships

BioMarin Pharmaceutical (TA-ERT acquisition)

Beyond the preview

Go deeper on Spruce Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spruce Ventures.

Explore the full profile